The post Is XRP Price Facing $45 Million Whale Dump Risk? appeared first on Coinpedia Fintech News The XRP price had momentum. Liquidity expanded during the rallyThe post Is XRP Price Facing $45 Million Whale Dump Risk? appeared first on Coinpedia Fintech News The XRP price had momentum. Liquidity expanded during the rally

Is XRP Price Facing $45 Million Whale Dump Risk?

2026/02/23 20:40
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
Ripple News

The post Is XRP Price Facing $45 Million Whale Dump Risk? appeared first on Coinpedia Fintech News

The XRP price had momentum. Liquidity expanded during the rally phase, USD depth grew, and the market had enough capital cushion to sustain upward moves. But now? That cushion is thinning.

Because, USD liquidity the capital depth supporting XRP markets has been declining. During the expansion phase, deeper liquidity allowed price to move higher without dramatic instability. Recently, though, that depth has faded. Thinner markets mean higher sensitivity. Volatility doesn’t need much fuel when the order books aren’t as thick as they used to be.

And that’s just one side of the equation.

Liquidity Compression Returns for XRP Price

On the token side, XRP liquidity had compressed noticeably before the previous breakout. Reduced active supply often precedes strong directional moves and that’s exactly what happened.

Now XRP liquidity is trending lower again, resembling those earlier pre-expansion conditions.

Is XRP Price Facing $45 Million Whale Dump Risk?

So why isn’t the XRP price ripping higher again?

Well, here’s the detail: since, whales are dumping but it appears to be preparing another exit door.

Data from CryptoQuant highlights a steady and systematic rise in cumulative whale inflows into Binance throughout 2026. Since January, the curve hasn’t spiked randomly, it’s climbed consistently. That’s why XRP price has been so sticky around $2 in 2025 and dipped to $1.40 presently.

Binance Whale Inflows Accelerate Fast

The acceleration became clearer in early February, per the latest query run on CryptoQuant’s Arab Chain dashboard. The pace of cumulative whale deposits increased compared to January, suggesting larger players are transferring balances to exchanges more aggressively.

Is XRP Price Facing $45 Million Whale Dump Risk?

Historically, increased whale flows to exchanges often coincide with short-term corrections or heightened volatility. With cumulative exchange flows rising, the theoretical liquidity available for sale is now higher than before.

This week alone saw more than 31 million XRP transferred to Binance in a single day.

Altogether, that’s nearly $45 million in potential sell-side pressure. Not catastrophic, but definitely worth watching on any XRP price chart.

Is XRP Price Facing $45 Million Whale Dump Risk?

XRP ETF Interest Fades

Meanwhile, inflows and outflows for the XRP ETF have slowed significantly. Reduced net activity signals fading momentum since launch. In plain terms, buyers aren’t stepping in aggressively and sellers aren’t rushing either.

Add in broader market indecision, with bitcoin ranging and offering little directional clarity, and altcoins like XRP are left without a strong macro tailwind.

Is XRP Price Facing $45 Million Whale Dump Risk?

So, If liquidity keeps thinning and whale deposits persist, recovery could remain capped in the near term. The XRP/USD pair doesn’t just need compressed supply, it needs demand to absorb it.
Until that balance shifts, the XRP price analysis suggests it may struggle to regain sustained upward momentum.

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.3666
$1.3666$1.3666
+0.74%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09